TESARO is a privately held, oncology-focused biopharmaceutical company founded in 2010 and headquartered in Waltham, Massachusetts. The company is developing rolapitant, a potent and selective NK1 receptor antagonist that completed Phase 2 testing for prevention of chemotherapy-induced nausea and vomiting and is planned to enter Phase 3 in 2011. TESARO is also advancing an ALK inhibitor program in-licensed from Amgen, targeting oncology indications including ALK-positive non-small cell lung cancer, with a first clinical trial targeted for 2012. In the thirteen months since founding the company in-licensed assets and built a pipeline focused on oncology and supportive care. TESARO previously raised a $20 million Series A in May 2010 and has secured a $101 million Series B to fund rolapitant through Phase 3, advance the ALK program into clinical trials, and expand its oncology product portfolio. TESARO is a Boston-based oncology-focused biopharmaceutical company developing and commercializing new cancer therapeutics and supportive care agents. The company intends to acquire, develop and commercialize cancer therapeutics and supportive care products. TESARO secured $60M in start-up funding to support those plans. Participants in a $20M Series A included New Enterprise Associates (NEA) and TESARO management, and NEA has reserved an additional $40M to support the company’s growth. The company was co-founded by former executives of MGI PHARMA, which was acquired by Eisai in 2008 for $3.9 billion. Its leadership team includes Lonnie Moulder (CEO), Mary Lynne Hedley, Ph.D. (President and CSO) and Rick Rodgers (EVP and CFO).

Total raised

$161M

Funding rounds

2

Latest round

Series B

Latest activity

Jun 2011